Effect of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) on chemotherapy-induced myelosuppression in patients with chronic lymphocytic leukemia: A crossover study

Leukemia and Lymphoma

Volumn 25, Issue 5-6, 1997, Pages 503-508

  Itälä, Maija ^a   Vanhatalo, Seppo ^b   Remes, Kari ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b SATAKUNTA CENTRAL HOSPITAL   (Finland)

Author keywords

Chronic lymphocytic leukemia; COP chemotherapy; Granulocyte macrophage colony stimulating factor

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINCRISTINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CANCER MORTALITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DYSPNEA; EOSINOPHILIA; ERYTHROCYTE TRANSFUSION; FEVER; HOSPITALIZATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEG EDEMA; MORBIDITY; MUSCLE HYPOTONIA; MUSCULOSKELETAL DISEASE; NEUTROPENIA; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX PAIN;

EID: 0030872334     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709039038     Document Type: Article

References (29)

1. American Society of Clinical Oncology. (1994). American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines, J. Clin. Oncol., 12, 2471-2508.
2. Harmenberg, J., Hogund, M. and Hellström-Lindberg, E. (1994) G- and GM-CSF in oncology and oncological haematology. Eur. J. Haematol., 52, 1-28
3. Vose, J. M. and Armitage, J. O. (1995). Clinical applications of hematopoietic growth factors, J. Clin. Oncol., 13, 1023-1035.
4. Itälä, M. and Remes, K. (1996). The COP regimen is not a feasible treatment for advanced, refractory chronic lymphocytic leukemia, Leuk. Lymphoma, in press.
5. Cytel Software Corporation. (1991). StatXact, statistical software for exact nonparametric inference, User manual version 2. Cambridge, MA, USA: Cytel Software Corporation.
6. Liepman, M. and Votaw, M. L. (1978). The treatment of chronic lymphocytic leukemia with COP chemotherapy, Cancer, 41, 1664-1669.
7. Oken, M. M. and Kaplan, E. K. (1979). Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia. Cancer. Treatm. Rep., 63, 441-447.
8. Montserrat, E., Alcala, A., Parody, R., et al. (1985). Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone, Cancer, 56, 2369-2375.
9. Biesma, B., de Vries, E. G. E., Willemse, P. H. B., et al. (1990). Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur. J. Cancer, 26, 932-936.
10. Kaplan, L. D., Kahn, J. O., Crowe, S., et al. (1991) Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomised trial, J. Clin. Oncol., 9, 929-940.
11. de Vries, E. G. E., Biesma, B., Willemse, P. H. B., et al. (1991). A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma, Cancer Res., 51, 116-122
12. Gerhartz, H. H., Engelhard, M., Meusers, P., et al. (1993). Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas, Blood, 82, 2329-2339.
13. Hamm, J. T., Schiller, J. H., Oken, M. M., et al. (1991). Granulocyte-macrophage colony-stimulating factor (GM-CSF) in small cell carcinoma of the lung (SCCL): preliminary analysis of a randomized controlled trial. Proc. Am. Soc Clin. Oncol., 10, 255 (abstr).
14. Ohno, R., Tomonaga, M., Kobayashi, T., et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N. Engl. J. Med., 323, 871-877.
15. Crawford, J., Ozer, H., Stoller, R., et al. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer, N. Engl. J. Med., 325, 164-170.
16. Pettengell, R., Gurney, G., Radford, J., et al. (1992). Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkins lymphoma: a randomised controlled trial, Blood, 80, 1430-1436.
17. Trillet-Lenoir, V., Green, J., Manegold, C., et al. (1993). Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy, Eur. J. Cancer, 29A. 319-324.
18. Nichols, C., Bajorin, D., Schmoll, H. J., et al. (1991). VIP chemotherapy with/without GM-CSF for poor risk, relapsed, or refractory germ cell tumors (GCT): preliminary analysis of a randomized controlled trial. Proc. Am. Soc Clin. Oncol., 10, 167 (abstr).
19. Bunn, P. A. Jr, Crowley, J., Kelly, K., et al. (1995) Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group, J. Clin Oncol., 13, 1632-1641.
20. Antman, K. S., Griffin, J. D., Elias, A., et al. (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression, N. Engl. J. Med., 319, 593-598.
21. Herrmann, F., Schulz, G., Wieser, M., et al. (1990). Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy, Am. J. Med., 88, 619-624.
22. Mughal, T. I. and O'Neill, K. (1994). A phase II study of recombinant granulocyte macrophage colony stimulating factor in patients with non-Hodgkin's lymphoma, Leuk. Lymphoma, 14, 331-334.
23. Kurzrock, R., Talpaz, M., Gomez, J. A., et al. (1991). Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low-over high-dose administration in selected patients, Br. J. Haematol., 78, 352-358.
24. Morstyn, G. (1990). The impact of colony stimulating factors on cancer chemotherapy, Br. J. Haematol., 75, 303-307.
25. Cebon, J., Lieschke, G. J., Bury, R. W., and Morstyn, G. (1992). The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. Br. J. Haematol., 80, 144-150.
26. Barlogie, B., Jagannath, S., Dixon, D. O., et al. (1990). High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma, Blood, 76, 677-680.
27. Edmonson, J. H., Long, H. J., and Kvols, L. K. (1994). Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgramostim enhance antisarcoma therapy? J. Natl. Cancer. Inst., 86, 312-314.
28. Ragnhammar, P., Fagerberg, J., Frödin, J. E., et al. (1993). Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcimona - long-lasting, complete remissions can be induced. Int. J. Cancer, 53, 751-758.
29. Itälä, M., Pelliniemi, T-T., Remes, K., and Vainio O. Effects of long-term treatment with GM-CSF on blood cell counts, lymphocyte subsets, and granulocyte functions in patients with chronic lymphocytic leukemia. Submitted for publication.